Direct vascular effects of HMG-CoA reductase inhibitors

Atherosclerosis

Volumn 137, Issue SUPPL., 1998, Pages

  Bellosta, Stefano ^a   Bernini, Franco ^b   Ferri, Nicola ^a   Quarato, Pierangelo ^a   Canavesi, Monica ^a   Arnaboldi, Lorenzo ^a   Fumagalli, Remo ^a   Paoletti, Rodolfo ^a   Corsini, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

AcLDL; Isoprenoids; Macrophages; SMC proliferation; Statins

Indexed keywords

CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PRAVASTATIN; SIMVASTATIN;

ANIMAL CELL; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CHOLESTEROL ESTERIFICATION; CONFERENCE PAPER; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RABBIT; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIES; ARTERIOSCLEROSIS; BLOOD VESSELS; CELL DIVISION; CELL MOVEMENT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES;

EID: 0031781834     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00319-5     Document Type: Conference Paper

References (66)

1. Gotto Jr. AM. The case for aggressive lipid regulation. Hosp Pract 1997:145-156.
2. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89:1329-1445.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
4. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
5. Havel RJ, Rapaport E. Management of primary hyperlipidemia. New Engl J Med 1995;332:1491-8.
6. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-82.
7. Alberts AW, Chen J, Kuron G, et al. Mevinolin: A highly potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980;77:3957-61.
8. Tsujita Y, Kuroda M, Shimada Y. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 1986;877:50-60.
9. Stokker GE, Hoffman WF, Alberts AW, et al. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 1. Structural modifications of 5-substituted 3,5-dihydroxypentanoic acids and their lactone derivatives. J Med Chem 1985;28:347-58.
10. Kathawala FG. HMG-CoA reductase inhibitors: An exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 1991;11:121-46.
11. Bakker-Arkema RJ, Davidsen MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J Am Med Assoc 1996;275:128-33.
12. Nash DT. Meeting national cholesterol education goals in clinical practice - A comparison of lovastatin and fluvastatin in primary prevention. Am J Cardiol 1996;78(Suppl 6A):26-31.
13. Hunninghake DB. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1992;3:22-8.
14. Feussner G. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1994;5:59-68.
15. Grunler J, Ericsson J, Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta 1994;1212:259-77.
16. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
17. Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 1993;104:19-26.
18. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;101:117-25.
19. Soma MR, Donetti E, Parolini C, et al. HMG-CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993;13:571-8.
20. Zhu BQ, Sievers RE, Sun YP, Isenberg WM, Parmley WW. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmacol 1992;19:246-55.
21. Gellman J, Ezekowitz MD, Sarembock IJ, et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty. A study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17:251-9.
22. Bocan TMA, Mazur MJ, Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: A biochemical and morphological evaluation. Atherosclerosis 1994;111:127-42.
23. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-9.
24. Wissler RW. Update on the pathogenesis of atherosclerosis. Am J Med 1991;91(Suppl 1B):1B-3S-1B-9S.
25. Schwartz CJ, Valente AJ, Sprague EA. A modern view of atherogenesis. Am J Cardiol 1993;71:9B-14.
26. Cleland JGF, Krikler DM. Modification of atherosclerosis by agents that do not lower cholesterol. Br Heart J 1993;69:S54-62.
27. Ip JH, Fuster V, Badimon L, Badimon J, Chesebro JH. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990;15:1667-87.
28. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of drug intervention: Focus on HMG-CoA reductase inhibitors. Am J Cardiol 1995;76:21A-8A.
29. Bernini F, Scurati N, Bonfadini G, Fumagalli R. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscler Thromb Vase Biol 1996;15:1352-8.
30. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-81.
31. Fernandez-Ortiz A, Badimon J, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. Am J Coll Cardiol 1994;23:1562-9.
32. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;2:941-4.
33. Burleigh MC, Briggs AD, Lendon CL, Davies MJ, Born GV, Richardson PD. Collagen types I and II, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: Snap-wise variations. Atherosclerosis 1992;96:71-81.
34. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-8.
35. Bellosta S, Canavesi M, Pfister P, Via D, Fumagalli R, Bernini F. Fluvastatin inhibition of MMP-9 activity secreted by macrophages, Abs 11th Int Symp Atheroscler Paris, 5-9 October 1997, published in Atherosclerosis, 1997;134:228.
36. Bourcier T, Aikawa M, Libby P. The HMG-CoA reductase inhibitors atorvastatin and lovastatin reduce accumulation of collagenase and 92-kD gelatinase released by cultured human monocytic and vascular smooth muscle cells. Abstract of the 11th International Symposium on Atherosclerosis Paris, 5-9 October 1997 published in Atherosclerosis 1997;134:121.
37. Maltese WA. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990;4:3319-28.
38. Glomset JA, Gelb MH, Farnsworth CC. Prenyl proteins in eukaryotic cells: A new type of membrane anchor. Trends Biochem Sci 1990;15:139-42.
39. Glomset JA, Farnsworth CC. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol 1994;10:181-205.
40. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. Human lamin B contains a farnesylated cysteine residue. J Biol Chem 1989;264:20422-9.
41. Casey PJ, Solsky PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989;86:8323-7.
42. kipl and facilitate the progression from Gl to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997;272:13-6.
43. Scott W. Hydrophilicity and the differential pharmacology of pravastatin. In: Wood C, editor. Lipid Management: Pravastatin and the Differential Pharmacology of HMG-CoA Reductase Inhibitors. London Round Table Series no. 16. London: Royal Society of Medicine Service, 1989:17-25.
44. Komai T, Shigehara E, Tokui T, et al. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 1992;43:667-70.
45. Igarashi M, Takeda Y, Mori S, Ishibashi N, Komatsu E, Takahashi K, Fuse T, Yamamura M, Kubo K, Sugiyama Y, Saito Y. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYW6228 and its inhibitory effect on vascular smooth muscle cell growth. Br J Pharmacol 1997;120:1172-8.
46. Bandoh T, Mitani H, Niihashi M, et al. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Eur J Pharmacol 1996;315:37-42.
47. Soma MR, Parolini C, Donetti E, Fumagalli R, Paoletti R. Inhibition of isoprenoid biosynthesis and arterial smooth muscle cell proliferation. J Cardiovasc Pharmacol 1995;25:S20-4.
48. Dain JG, Fu E, Gorski J, Nicoletti J, Scallen TJ. Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 1993;21:567-72.
49. Tse FLS, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses of normal volunteers. J Clin Pharmacol 1992;32:630-8.
50. Pentikainen P, Saraheimo M, Schwartz J, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992;32:136-40.
51. Soma MR, Baetta R, De Renzis MR, Mazzini G, Davegna C, Magrassi L, Butti G, Pezzotta S, Paoletti R, Fumagalli R. In vivo enhanced antitumor activity of carmustine [N,N'-Bis(2-chloroethyl)-Af-nitrosourea] by simvastatin. Cancer Res 1995;55:597-602.
52. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest 1985;76:1748-54.
53. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoproteins and Coronary Atherosclerosis Study (LCAS)). Am J Cardiol 1997;80:278-86.
54. Foley DP, Bonnier H, Jackson G, Macaya C, Shepherd J, Vrolix M, Serruys PW. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. Am J Cardiol 1994;73:50D-61.
55. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vase Biol 1997;17:265-72.
56. Kleinveld HA, Demacker PNM, De Haan AFJ, Stalenhoef AFH. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest 1993;23:289-95.
57. Hussein O, Schlezinger S, Rosenblat M, Kheidar S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997;128:11-8.
58. Kobashigawa JA, Katznelson S, Hillel L, Johnson JA, Yeatman L, Wang XM. Effect of pravastatin on outcomes after cardiac transplantation. New Engl J Med 1995;333:621-7.
59. Umetani N, Kanayama Y, Okamura M, Negoro N, Takeda T. Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages. Biochim Biophys Acta 1996;1303:199-206.
60. La Ville A, Moshy R, Turner PR, Miller NE, Lewis B. Inhibition of cholesterol synthesis reduces low density lipoprotein apoprotein B production without decreasing very low density lipoprotein apoprotein B synthesis in rabbits. Biochem J 1984;218:321-3.
61. Giroux LM, Davignon J, Naruzewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993;1165:335-8.
62. Masaaki K, Kurose I, Russell J, Granger DN. Effect of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vase Biol 1997;17:1521-6.
63. Sakai M, Kobori S, Matsumura T, Biwa T, Sato Y, Takemura T, Hakamata H, Horiuchi S, Shichiri M. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997;133:51-9.
64. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;345:1274-5.
65. Corsini A, Arnaboldi L, Raiteri M, Quarato P, Faggiotto A, Paoletti R, Fumagalli R. Effect of the new HMG-CoA reductase inhibitor cerivastatin (Bay W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res 1996;33:56-61.
66. Raiteri M, Arnaboldi L, McGeady P, Gelb MH, Verri D, Tagliabue C, Quarato P, Ferraboschi P, Santaniello E, Paoletti R, Fumagalli R, Corsini A. Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 1997;281:1144-53.